First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2026-01-15
Target enrollment:
Participant gender:
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and
antitumor activity of TORL-2-307-ADC in patients with advanced cancer